Brian Orelli, PhD

Are big biotechs -- Amgen, Biogen Idec, Gilead Sciences, and Celgene -- really overvalued, or is the Fed chairwoman looking at smaller companies?

Good news from Exelixis' partner Roche, but we don't know if the trial data is good enough to beat GlaxoSmithKline's competing regimen.

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.

Gilead's Sciences' idelalisib will be used in combination with Roche and Biogen Idec's Rituxan. An FDA approval is key, with Infinity Pharmaceuticals hot on its heels.

MannKind is going to have a hard time competing with Novo Nordisk and Eli Lilly, especially in type 1 diabetics.

MannKind's Afrezza is approved but can it compete with injected insulin from Novo Nordisk and Eli Lilly?

An FDA advisory committee recommends against accelerated approval for olaparib, potentially justifying a lower bid from Pfizer.

Vertex Pharmaceuticals cystic fibrosis combination looks good enough to get approved and knock down sales of antibiotics from Gilead Sciences and Novartis.

Geron gets a clinical hold released, but is still a ways away from competing with Incyte's Jakafi.

Three health care stocks to consider for your watchlist.

A positive result at an FDA advisory committee for AstraZeneca's olaparib, which will compete with AbbVie's veliparib, could make the British company more attractive to Pfizer.

Do Amarin, Prosensa, and Jazz Pharmaceuticals deserve a goal, a yellow card, or a straight stay-away red card?

Hepatitis C acquisitions like we've seen from Gilead, Bristol-Myers Squibb, and Merck can't last forever.

Investors can learn something from Medivation, GlaxoSmithKline, Amarin and AstraZeneca.

Delayed approval of Orexigen Therapeutics' Contrave won't hurt the company much, and it won't help competitors Arena Pharmaceuticals and VIVUS, either.

Whether Cubist Pharmaceuticals or Durata Therapeutics wins remains to be seen, but both might be able to beat Pfizer's older drug.

Verastem might have to compete with GlaxoSmithKine, but Eli Lilly won't be a problem since it's targeting patients that have already taken Lilly's drug.

Zafgen IPOs, but investors in Arena Pharmaceuticals, VIVUS and Orexigen don't have to be worried just yet.